Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on CKD-395 PK in Healthy Males
NCT02648854Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Oct 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lobeglitazone and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the Last Measurable Concentration and Maximum Plasma Concentration. Started Oct 2015; status: completed.
02
Drugs
lobeglitazoneliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02648854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02648854.